Kamada - Asset Resilience Ratio
Kamada (KMDA) has an Asset Resilience Ratio of 0.00% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Kamada to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2021)
This chart shows how Kamada's Asset Resilience Ratio has changed over time. See KMDA equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kamada's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Kamada.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA0.00 | 0% |
| Total Liquid Assets | ILA0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kamada maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kamada Industry Peers by Asset Resilience Ratio
Compare Kamada's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Kamada (2009–2021)
The table below shows the annual Asset Resilience Ratio data for Kamada.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | ILA0.00 ≈ $0.00 |
ILA318.67 Million ≈ $854.34K |
-- |
| 2020-12-31 | 18.55% | ILA39.07 Million ≈ $104.74K |
ILA210.66 Million ≈ $564.79K |
+0.57pp |
| 2019-12-31 | 17.98% | ILA31.25 Million ≈ $83.77K |
ILA173.80 Million ≈ $465.94K |
-5.55pp |
| 2018-12-31 | 23.53% | ILA32.50 Million ≈ $87.13K |
ILA138.12 Million ≈ $370.28K |
-1.31pp |
| 2017-12-31 | 24.84% | ILA30.34 Million ≈ $81.34K |
ILA122.11 Million ≈ $327.37K |
+6.12pp |
| 2016-12-31 | 18.72% | ILA18.66 Million ≈ $50.04K |
ILA99.70 Million ≈ $267.28K |
-4.08pp |
| 2015-12-31 | 22.80% | ILA23.26 Million ≈ $62.36K |
ILA101.99 Million ≈ $273.44K |
-8.42pp |
| 2014-12-31 | 31.22% | ILA37.35 Million ≈ $100.13K |
ILA119.62 Million ≈ $320.69K |
+20.41pp |
| 2013-12-31 | 10.81% | ILA15.07 Million ≈ $40.39K |
ILA139.38 Million ≈ $373.67K |
-8.19pp |
| 2012-12-31 | 19.00% | ILA16.93 Million ≈ $45.39K |
ILA89.11 Million ≈ $238.91K |
-0.74pp |
| 2011-12-31 | 19.74% | ILA16.87 Million ≈ $45.22K |
ILA85.45 Million ≈ $229.09K |
-2.51pp |
| 2010-12-31 | 22.25% | ILA20.36 Million ≈ $54.60K |
ILA91.52 Million ≈ $245.37K |
+21.41pp |
| 2009-12-31 | 0.84% | ILA527.72K ≈ $1.41K |
ILA62.91 Million ≈ $168.66K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more